Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Alterations in the retinal vasculature occur in multiple sclerosis and exhibit novel correlations with disability and visual function measures.

Murphy OC, Kwakyi O, Iftikhar M, Zafar S, Lambe J, Pellegrini N, Sotirchos ES, Gonzalez-Caldito N, Ogbuokiri E, Filippatou A, Risher H, Cowley N, Feldman S, Fioravante N, Frohman EM, Frohman TC, Balcer LJ, Prince JL, Channa R, Calabresi PA, Saidha S.

Mult Scler. 2019 May 16:1352458519845116. doi: 10.1177/1352458519845116. [Epub ahead of print]

PMID:
31094280
2.

Cerebellar syndrome in a man treated with natalizumab: From the National Multiple Sclerosis Society Case Conference Proceedings.

Lapides DA, Batchala PP, Donahue JH, Lisak RP, Meltzer EI, Narayan RN, Nath A, Frohman TC, Costello K, Goldman MD, Zamvil SS, Frohman EM.

Neurol Neuroimmunol Neuroinflamm. 2019 Mar 7;6(3):e546. doi: 10.1212/NXI.0000000000000546. eCollection 2019 May. No abstract available.

3.

Retinal measurements predict 10-year disability in multiple sclerosis.

Rothman A, Murphy OC, Fitzgerald KC, Button J, Gordon-Lipkin E, Ratchford JN, Newsome SD, Mowry EM, Sotirchos ES, Syc-Mazurek SB, Nguyen J, Caldito NG, Balcer LJ, Frohman EM, Frohman TC, Reich DS, Crainiceanu C, Saidha S, Calabresi PA.

Ann Clin Transl Neurol. 2019 Jan 19;6(2):222-232. doi: 10.1002/acn3.674. eCollection 2019 Feb.

4.

A young man in "double-trouble": Hallucinations and cranial nerve palsies: From the National Multiple Sclerosis Society Case Conference Proceedings.

Bradshaw MJ, Lisak RP, Meltzer E, Melamed E, Lucas A, Freeman L, Frohman TC, Costello K, Balcer L, Galetta S, Chitnis T, Zamvil SS, Frohman EM.

Neurol Neuroimmunol Neuroinflamm. 2018 Dec 19;6(1):e526. doi: 10.1212/NXI.0000000000000526. eCollection 2019 Jan. No abstract available.

5.

A young man with numbness in arms and legs: From the National Multiple Sclerosis Society Case Conference Proceedings.

Romeo AR, Lisak RP, Meltzer E, Fox EJ, Melamed E, Lucas A, Freeman L, Frohman TC, Costello K, Zamvil SS, Frohman EM, Gelfand JM.

Neurol Neuroimmunol Neuroinflamm. 2018 Oct 23;5(6):e509. doi: 10.1212/NXI.0000000000000509. eCollection 2018 Nov. No abstract available.

6.

Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study.

Caldito NG, Saidha S, Sotirchos ES, Dewey BE, Cowley NJ, Glaister J, Fitzgerald KC, Al-Louzi O, Nguyen J, Rothman A, Ogbuokiri E, Fioravante N, Feldman S, Kwakyi O, Risher H, Kimbrough D, Frohman TC, Frohman E, Balcer L, Crainiceanu C, Van Zijl PCM, Mowry EM, Reich DS, Oh J, Pham DL, Prince J, Calabresi PA.

Brain. 2018 Nov 1;141(11):3115-3129. doi: 10.1093/brain/awy245.

PMID:
30312381
7.

Should Spinal MRI Be Routinely Performed in Patients With Clinically Isolated Optic Neuritis?

Meltzer E, Frohman EM, Costello FE, Burton JM, Frohman TC.

J Neuroophthalmol. 2018 Dec;38(4):502-510. doi: 10.1097/WNO.0000000000000685. No abstract available.

PMID:
30001224
8.

Visual Pathway Measures are Associated with Neuropsychological Function in Multiple Sclerosis.

Nguyen J, Rothman A, Fitzgerald K, Whetstone A, Syc-Mazurek S, Aquino J, Balcer LJ, Frohman EM, Frohman TC, Crainiceanu C, Beier M, Newsome SD, Calabresi PA, Saidha S.

Curr Eye Res. 2018 Jul;43(7):941-948. doi: 10.1080/02713683.2018.1459730. Epub 2018 May 1.

9.

Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon.

Sobhanian MJ, Agarwal R, Meltzer E, Kildebeck E, Frohman BS, Frohman AN, Galetta SL, Saidha S, White O, Villoslada P, Paul F, Petzold A, Rennaker RL, Martinez-Lapiscina EH, Balcer LJ, Kardon R, Frohman EM, Frohman TC.

J Neurol Sci. 2018 Apr 15;387:60-69. doi: 10.1016/j.jns.2018.01.029. Epub 2018 Feb 3.

PMID:
29571874
10.

Preserved canonicality of the BOLD hemodynamic response reflects healthy cognition: Insights into the healthy brain through the window of Multiple Sclerosis.

Turner MP, Hubbard NA, Sivakolundu DK, Himes LM, Hutchison JL, Hart J Jr, Spence JS, Frohman EM, Frohman TC, Okuda DT, Rypma B.

Neuroimage. 2019 Apr 15;190:46-55. doi: 10.1016/j.neuroimage.2017.12.081. Epub 2018 Feb 15. Review.

PMID:
29454932
11.

New Ways of "Seeing" the Mechanistic Heterogeneity of Multiple Sclerosis Plaque Pathogenesis.

Meltzer EI, Costello FE, Frohman EM, Frohman TC.

J Neuroophthalmol. 2018 Mar;38(1):91-100. doi: 10.1097/WNO.0000000000000633. Review.

PMID:
29438266
12.

Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis.

Nolan RC, Galetta SL, Frohman TC, Frohman EM, Calabresi PA, Castrillo-Viguera C, Cadavid D, Balcer LJ.

J Neuroophthalmol. 2018 Dec;38(4):451-458. doi: 10.1097/WNO.0000000000000629.

PMID:
29384802
13.

Visual Fixation Instability in Multiple Sclerosis Measured Using SLO-OCT.

Mallery RM, Poolman P, Thurtell MJ, Full JM, Ledolter J, Kimbrough D, Frohman EM, Frohman TC, Kardon RH.

Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):196-201. doi: 10.1167/iovs.17-22391.

PMID:
29340646
14.

Analysis of Agreement of Retinal-Layer Thickness Measures Derived from the Segmentation of Horizontal and Vertical Spectralis OCT Macular Scans.

Gonzalez Caldito N, Antony B, He Y, Lang A, Nguyen J, Rothman A, Ogbuokiri E, Avornu A, Balcer L, Frohman E, Frohman TC, Bhargava P, Prince J, Calabresi PA, Saidha S.

Curr Eye Res. 2018 Mar;43(3):415-423. doi: 10.1080/02713683.2017.1406526. Epub 2017 Dec 14.

15.

Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.

Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ; ERN-EYE IMSVISUAL.

Lancet Neurol. 2017 Oct;16(10):797-812. doi: 10.1016/S1474-4422(17)30278-8. Epub 2017 Sep 12. Review.

PMID:
28920886
16.

Calibrated imaging reveals altered grey matter metabolism related to white matter microstructure and symptom severity in multiple sclerosis.

Hubbard NA, Turner MP, Ouyang M, Himes L, Thomas BP, Hutchison JL, Faghihahmadabadi S, Davis SL, Strain JF, Spence J, Krawczyk DC, Huang H, Lu H, Hart J Jr, Frohman TC, Frohman EM, Okuda DT, Rypma B.

Hum Brain Mapp. 2017 Nov;38(11):5375-5390. doi: 10.1002/hbm.23727. Epub 2017 Aug 16.

17.

Capturing saccades in multiple sclerosis with a digitized test of rapid number naming.

Hainline C, Rizzo JR, Hudson TE, Dai W, Birkemeier J, Raynowska J, Nolan RC, Hasanaj L, Selesnick I, Frohman TC, Frohman EM, Galetta SL, Balcer LJ, Rucker JC.

J Neurol. 2017 May;264(5):989-998. doi: 10.1007/s00415-017-8484-1. Epub 2017 Apr 7.

18.

Retinal Architecture and Melanopsin-Mediated Pupillary Response Characteristics: A Putative Pathophysiologic Signature for the Retino-Hypothalamic Tract in Multiple Sclerosis.

Meltzer E, Sguigna PV, Subei A, Beh S, Kildebeck E, Conger D, Conger A, Lucero M, Frohman BS, Frohman AN, Saidha S, Galetta S, Calabresi PA, Rennaker R, Frohman TC, Kardon RH, Balcer LJ, Frohman EM.

JAMA Neurol. 2017 May 1;74(5):574-582. doi: 10.1001/jamaneurol.2016.5131.

19.

High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes.

Beh SC, Kildebeck E, Narayan R, Desena A, Schell D, Rowe ES, Rowe V, Burns D, Whitworth L, Frohman TC, Greenberg B, Frohman EM.

J Neurol Sci. 2017 Jan 15;372:187-195. doi: 10.1016/j.jns.2016.11.012. Epub 2016 Nov 15.

PMID:
28017209
20.

The emergence of neuroepidemiology, neurovirology and neuroimmunology: the legacies of John F. Kurtzke and Richard 'Dick' T. Johnson.

Kildebeck EJ, Narayan R, Nath A, Weiner H, Beh S, Calabresi PA, Steinman L, Major EO, Frohman TC, Frohman EM.

J Neurol. 2017 Apr;264(4):817-828. doi: 10.1007/s00415-016-8293-y. Epub 2016 Oct 12. No abstract available.

PMID:
27734166
21.

Cerebellar Control of Eye Movements.

Beh SC, Frohman TC, Frohman EM.

J Neuroophthalmol. 2017 Mar;37(1):87-98. doi: 10.1097/WNO.0000000000000456. Review.

PMID:
27643747
22.

Neurotherapeutic Strategies for Multiple Sclerosis.

Frohman TC, Beh SC, Kildebeck EJ, Narayan R, Treadaway K, Frohman EM.

Neurol Clin. 2016 Aug;34(3):483-523. doi: 10.1016/j.ncl.2016.05.001. Review. Erratum in: Neurol Clin. 2016 Nov;34(4):xv.

PMID:
27445239
23.

In Memoriam: John F. Kurtzke, MD (1926-2015): A Founding Father of Neuroepidemiology and Pioneer of Modern Clinical Trial Design.

Frohman EM, Stüve O, Frohman TC, Lisak R.

JAMA Neurol. 2016 Apr;73(4):482-3. doi: 10.1001/jamaneurol.2016.0030. No abstract available.

PMID:
27064556
24.

Extended interval dosing of natalizumab in multiple sclerosis.

Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, Rimler Z, Green R, Monson N, Hoyt T, Bradshaw M, Fallon J, Chamot E, Bucello M, Beh S, Cutter G, Major E, Herbert J, Frohman EM.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):885-9. doi: 10.1136/jnnp-2015-312940. Epub 2016 Feb 25.

PMID:
26917698
25.

Ocular motor signatures of cognitive dysfunction in multiple sclerosis.

Fielding J, Clough M, Beh S, Millist L, Sears D, Frohman AN, Lizak N, Lim J, Kolbe S, Rennaker RL 2nd, Frohman TC, White OB, Frohman EM.

Nat Rev Neurol. 2015 Nov;11(11):637-45. doi: 10.1038/nrneurol.2015.174. Epub 2015 Sep 15. Review.

PMID:
26369516
26.

Aquatic training in MS: neurotherapeutic impact upon quality of life.

Frohman AN, Okuda DT, Beh S, Treadaway K, Mooi C, Davis SL, Shah A, Frohman TC, Frohman EM.

Ann Clin Transl Neurol. 2015 Aug;2(8):864-72. doi: 10.1002/acn3.220. Epub 2015 Jun 26.

27.

Asynchrony in executive networks predicts cognitive slowing in multiple sclerosis.

Hubbard NA, Hutchison JL, Turner MP, Sundaram S, Oasay L, Robinson D, Strain J, Weaver T, Davis SL, Remington GM, Huang H, Biswal BB, Hart J, Frohman TC, Frohman EM, Rypma B.

Neuropsychology. 2016 Jan;30(1):75-86. doi: 10.1037/neu0000202. Epub 2015 Jul 6.

PMID:
26146853
28.

Ocular motor measures of cognitive dysfunction in multiple sclerosis I: inhibitory control.

Clough M, Millist L, Lizak N, Beh S, Frohman TC, Frohman EM, White OB, Fielding J.

J Neurol. 2015 May;262(5):1130-7. doi: 10.1007/s00415-015-7645-3. Epub 2015 Apr 9.

PMID:
25851743
29.

Ocular motor measures of cognitive dysfunction in multiple sclerosis II: working memory.

Clough M, Mitchell L, Millist L, Lizak N, Beh S, Frohman TC, Frohman EM, White OB, Fielding J.

J Neurol. 2015 May;262(5):1138-47. doi: 10.1007/s00415-015-7644-4. Epub 2015 Apr 9.

PMID:
25851742
30.

Neuro-ophthalmic manifestations of cerebellar disease.

Beh SC, Frohman TC, Frohman EM.

Neurol Clin. 2014 Nov;32(4):1009-80. doi: 10.1016/j.ncl.2014.07.002. Epub 2014 Oct 24. Review.

PMID:
25439294
31.

Retinal damage and vision loss in African American multiple sclerosis patients.

Kimbrough DJ, Sotirchos ES, Wilson JA, Al-Louzi O, Conger A, Conger D, Frohman TC, Saidha S, Green AJ, Frohman EM, Balcer LJ, Calabresi PA.

Ann Neurol. 2015 Feb;77(2):228-36. doi: 10.1002/ana.24308. Epub 2015 Jan 13.

32.

Retinal architecture and mfERG: Optic nerve head component response characteristics in MS.

Schnurman ZS, Frohman TC, Beh SC, Conger D, Conger A, Saidha S, Galetta S, Calabresi PA, Green AJ, Balcer LJ, Frohman EM.

Neurology. 2014 May 27;82(21):1888-96. doi: 10.1212/WNL.0000000000000447. Epub 2014 Apr 30.

33.

An update on neuro-ophthalmology of multiple sclerosis: the visual system as a model to study multiple sclerosis.

Qureshi SS, Beh SC, Frohman TC, Frohman EM.

Curr Opin Neurol. 2014 Jun;27(3):300-8. doi: 10.1097/WCO.0000000000000098. Review.

PMID:
24751959
34.

JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.

Frohman EM, Monaco MC, Remington G, Ryschkewitsch C, Jensen PN, Johnson K, Perkins M, Liebner J, Greenberg B, Monson N, Frohman TC, Douek D, Major EO.

JAMA Neurol. 2014 May;71(5):596-602. doi: 10.1001/jamaneurol.2014.63.

PMID:
24664166
35.

Isolated mammillary body involvement on MRI in Wernicke's encephalopathy.

Beh SC, Frohman TC, Frohman EM.

J Neurol Sci. 2013 Nov 15;334(1-2):172-5. doi: 10.1016/j.jns.2013.07.2516. Epub 2013 Aug 2.

PMID:
23953677
36.

Optic nerve head component responses of the multifocal electroretinogram in MS.

Frohman TC, Beh SC, Saidha S, Schnurman Z, Conger D, Conger A, Ratchford JN, Lopez C, Galetta SL, Calabresi PA, Balcer LJ, Green AJ, Frohman EM.

Neurology. 2013 Aug 6;81(6):545-51. doi: 10.1212/WNL.0b013e31829e6faa. Epub 2013 Jul 3.

37.

Uhthoff's phenomena in MS--clinical features and pathophysiology.

Frohman TC, Davis SL, Beh S, Greenberg BM, Remington G, Frohman EM.

Nat Rev Neurol. 2013 Sep;9(9):535-40. doi: 10.1038/nrneurol.2013.98. Epub 2013 Jun 4. Review.

PMID:
23732530
38.

Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis.

Saidha S, Sotirchos ES, Oh J, Syc SB, Seigo MA, Shiee N, Eckstein C, Durbin MK, Oakley JD, Meyer SA, Frohman TC, Newsome S, Ratchford JN, Balcer LJ, Pham DL, Crainiceanu CM, Frohman EM, Reich DS, Calabresi PA.

JAMA Neurol. 2013 Jan;70(1):34-43. doi: 10.1001/jamaneurol.2013.573.

39.

Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning.

Ratchford JN, Saidha S, Sotirchos ES, Oh JA, Seigo MA, Eckstein C, Durbin MK, Oakley JD, Meyer SA, Conger A, Frohman TC, Newsome SD, Balcer LJ, Frohman EM, Calabresi PA.

Neurology. 2013 Jan 1;80(1):47-54. doi: 10.1212/WNL.0b013e31827b1a1c.

40.

Objective characterization of the relative afferent pupillary defect in MS.

Blazek P, Davis SL, Greenberg BM, Conger A, Conger D, Vernino S, Beh S, Stuve O, Saidha S, Ratchford JN, Green A, Calabresi PA, Balcer LJ, Frohman TC, Frohman EM.

J Neurol Sci. 2012 Dec 15;323(1-2):193-200. doi: 10.1016/j.jns.2012.09.015. Epub 2012 Sep 29.

PMID:
23026533
41.

Multifocal visual evoked potentials are influenced by variable contrast stimulation in MS.

Frohman AR, Schnurman Z, Conger A, Conger D, Beh S, Greenberg B, Sutter E, Calabresi PA, Balcer LJ, Frohman TC, Frohman EM.

Neurology. 2012 Aug 21;79(8):797-801. doi: 10.1212/WNL.0b013e3182661edc. Epub 2012 Jul 18.

42.

Current and emerging therapies in multiple sclerosis: a systematic review.

Castro-Borrero W, Graves D, Frohman TC, Flores AB, Hardeman P, Logan D, Orchard M, Greenberg B, Frohman EM.

Ther Adv Neurol Disord. 2012 Jul;5(4):205-20. doi: 10.1177/1756285612450936.

43.

In vivo assessment of retinal neuronal layers in multiple sclerosis with manual and automated optical coherence tomography segmentation techniques.

Seigo MA, Sotirchos ES, Newsome S, Babiarz A, Eckstein C, Ford E, Oakley JD, Syc SB, Frohman TC, Ratchford JN, Balcer LJ, Frohman EM, Calabresi PA, Saidha S.

J Neurol. 2012 Oct;259(10):2119-30. doi: 10.1007/s00415-012-6466-x. Epub 2012 Mar 15.

PMID:
22418995
44.

Modeling the mechanisms of Uhthoff's phenomenon in MS patients with internuclear ophthalmoparesis.

Frohman TC, Davis SL, Frohman EM.

Ann N Y Acad Sci. 2011 Sep;1233:313-9. doi: 10.1111/j.1749-6632.2011.06125.x.

PMID:
21951010
45.

Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.

Saidha S, Syc SB, Durbin MK, Eckstein C, Oakley JD, Meyer SA, Conger A, Frohman TC, Newsome S, Ratchford JN, Frohman EM, Calabresi PA.

Mult Scler. 2011 Dec;17(12):1449-63. doi: 10.1177/1352458511418630. Epub 2011 Aug 24.

PMID:
21865411
46.

The impact of utilizing different optical coherence tomography devices for clinical purposes and in multiple sclerosis trials.

Warner CV, Syc SB, Stankiewicz AM, Hiremath G, Farrell SK, Crainiceanu CM, Conger A, Frohman TC, Bisker ER, Balcer LJ, Frohman EM, Calabresi PA, Saidha S.

PLoS One. 2011;6(8):e22947. doi: 10.1371/journal.pone.0022947. Epub 2011 Aug 11.

47.

Symptomatic therapy in multiple sclerosis.

Frohman TC, Castro W, Shah A, Courtney A, Ortstadt J, Davis SL, Logan D, Abraham T, Abraham J, Remington G, Treadaway K, Graves D, Hart J, Stuve O, Lemack G, Greenberg B, Frohman EM.

Ther Adv Neurol Disord. 2011 Mar;4(2):83-98. doi: 10.1177/1756285611400658.

48.

Functional treatments in multiple sclerosis.

Courtney AM, Castro-Borrero W, Davis SL, Frohman TC, Frohman EM.

Curr Opin Neurol. 2011 Jun;24(3):250-4. doi: 10.1097/WCO.0b013e328346055a. Review.

PMID:
21455067
49.

Cup to disc ratio by optical coherence tomography is abnormal in multiple sclerosis.

Syc SB, Warner CV, Saidha S, Farrell SK, Conger A, Bisker ER, Wilson J, Frohman TC, Frohman EM, Balcer LJ, Calabresi PA.

J Neurol Sci. 2011 Mar 15;302(1-2):19-24. doi: 10.1016/j.jns.2010.12.011. Epub 2011 Jan 11.

50.

A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.

Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, Durfee JE, Conger A, Carl E, Treadaway K, Lindzen E, Salter A, Frohman TC, Shah A, Bates A, Cox JL, Dwyer MG, Stüve O, Greenberg BM, Racke MK, Zivadinov R.

Ther Adv Neurol Disord. 2010 Jan;3(1):15-28. doi: 10.1177/1756285609353354.

Supplemental Content

Loading ...
Support Center